Table 2 DVT risk assessment and prevention of the two groups before and after PSM

 Padua low risk

33 (5.1%)

1 (2.2%)

32 (5.3%)

0.502

1 (2.2%)

4 (2.3%)

> 0.999

 Padua high risk

169 (26%)

10 (21.3%)

159 (26.4%)

0.443

10 (21.3%)

32 (18.9%)

0.720

 Caprini very low and low risk

3

0

3

> 0.999

–

 Caprini moderate risk

49 (7.5%)

3 (6.4%)

46 (7.6%)

> 0.999

3 (6.4%)

8 (1.3%)

0.708

 Caprini high risk

337 (51.8%)

32 (68.0%)

305 (50.6%)

0.021

32 (68.0%)

115 (68.0%)

0.096

 Wells low-to-moderate risk

58 (8.9%)

1 (2.1%)

57 (9.5%)

0.110

1 (2.1%)

10 (5.9%)

0.463

 Wells high risk

1 (0.2%)

0

1 (0.2%)

> 0.999

–

 Within 24 h of admission

411 (63.2%)

21 (44.7%)

390 (64.7%)

0.006

21 (44.7%)

110 (65.1%)

0.011

 24-48 h of admission

201 (30.9%)

22 (46.8%)

179 (29.7%)

0.064

22 (46.8%)

53 (31.3%)

0.049

 When disease conditions change

33 (5.1%)

18 (38.3%)

15 (2.5%)

< 0.001

18 (38.3%)

5 (3.0%)

< 0.001

 Routinely

98 (15.1%)

8 (17.0%)

90 (14.9%)

0.699

8 (17.0%)

31 (18.3%)

0.835

 Basic prophylaxis

562 (86.5%)

26 (55.3%)

536 (88.9%)

< 0.001

26 (55.3%)

158 (93.5%)

< 0.001

 Physical prophylaxis

469 (72.2%)

19 (40.4%)

450 (74.6%)

< 0.001

19 (40.4%)

144 (85.2%)

< 0.001

 Pharmaceutical prophylaxis

169 (26.0%)

8 (17.0%)

161(26.7%)

0.145

8 (17.0%)

38 (22.5%)

0.418

  Low molecular weight heparin

126 (74.6%)

5 (62.5%)

121 (75.2%)

0.631

5 (62.5%)

30 (78.9%)

0.793

  Unfractionated heparin

3 (1.8%)

0

3 (1.9%)

0.737

0

2 (5.3%)

0.432

  Warfarin

5 (3.0%)

1 (12.5%)

4 (24.8%)

0.562

1 (12.5%)

0

0.135

  Factor Xa inhibitor

1 (0.6%)

1 (12.5%)

0

0.012

1 (12.5%)

0

0.012

  Factor IIA inhibitor

1 (0.6%)

0

1 (0.6%)

0.847

0

1 (2.6%)

0.847

  Antiplatelet

33 (19.5%)

1 (12.5%)

32 (19.9%)

0.209

1 (12.5%)

5 (13.2%)

0.536